Sunshine Guojian Pharmaceutical announced that the company has received the "Acceptance Notice" issued by the National Medical Products Administration, and the clinical trial application for SSGJ-627 injection has been accepted. SSGJ-627 injection is an innovative research and development product of Sunshine Guojian Pharmaceutical, with independent intellectual property rights, and is a recombinant anti-TL1A humanized monoclonal antibody. So far, the clinical trial application for SSGJ-627 injection has been accepted, making it the first domestically produced TL1A antibody to be accepted. Preclinical studies show that SSGJ-627 has a high affinity and specific binding to TL1A, demonstrating significant efficacy in various animal models. At the same time, SSGJ-627 has good and acceptable safety.
三生国健:SSGJ-627注射液临床试验申请获受理
Sunshine Guojian Pharmaceutical: The clinical trial application for SSGJ-627 injection has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.